This product page is intended for qualified business, laboratory, or research-related inquiry. Availability and permitted use depend on destination country and local regulations.
Confirm product name, preferred specification, quantity, and packaging requirement before quotation.
Ask for available specification sheet, packaging details, or product-related quality documentation.
Use Inquiry Cart or the quote form so our team can reply with availability, lead time, and shipping communication.
ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes.ARA 290 has been shown to be effective in the reduction of inflammation and activation of the healing process in a wide variety of preclinical models as well as in patients.
With respect to diabetes, substantial recent work has shown that rhEPO can improve the diabetic state in animal models . However, in addition to interacting with the innate repair receptor in a paracrine/autocrine manner, EPO also functions as a circulating hormone via its interaction with the EPO receptor homodimer that mediates hematopoiesis.
Request a Quote
Send your quantity, destination country, and preferred contact method. Our team will reply with availability and quotation details.